Viracta Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Viracta Therapeutics has a total shareholder equity of $11.1M and total debt of $18.7M, which brings its debt-to-equity ratio to 168.6%. Its total assets and total liabilities are $41.3M and $30.3M respectively.
Key information
168.6%
Debt to equity ratio
US$18.68m
Debt
| Interest coverage ratio | n/a |
| Cash | US$39.57m |
| Equity | US$11.08m |
| Total liabilities | US$30.25m |
| Total assets | US$41.33m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RYI's short term assets ($41.0M) exceed its short term liabilities ($30.3M).
Long Term Liabilities: RYI has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: RYI has more cash than its total debt.
Reducing Debt: RYI's debt to equity ratio has increased from 129.2% to 168.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RYI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RYI has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 28% each year.